European evidence based consensus on the diagnosis and management of Crohn's disease: Current management

Gut

Volumn 55, Issue SUPPL. 1, 2006, Pages

  Travis, S P L ^a   Stange, E F ^b   Lemann M ^c   Oresland T ^d   Chowers, Y ^e   Forbes, A ^f   D'Haens, G ^g   Kitis, G ^g   Cortot, A ^h   Prantera, C ⁱ   Marteau, P ^j   Colombel, J F ^h   Gionchetti, P ^k   Bouhnik, Y ^l   Tiret, E ^m,n   Kroesen, J ^o   Starlinger, M ^p   Mortensen, N J McM ^q  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c SAINT LOUIS HOSPITAL   (France)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e SHEBA MEDICAL CENTER   (Israel)

^f UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^g IMELDA HOSPITAL   (Belgium)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^j Hospital Européen   (France)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l HÔPITAL LARIBOISIÈRE   (France)

^m INSERM   (France)

ⁿ SORBONNE UNIVERSITÉ   (France)

^o CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^p UNIVERSITY OF GRAZ   (Austria)

^q John Radcliffe ^*  (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALICAFORSEN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIMETABOLITE; ANTIMYCOBACTERIAL AGENT; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; NATALIZUMAB; PARACETAMOL; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; SALAZOSULFAPYRIDINE; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; 5 ACETAMIDOSALICYLIC ACID; FISH OIL; FONTOLIZUMAB; INTERLEUKIN 10; MYCOPHENOLATE MOFETIL; OMEGA 3 FATTY ACID; PLACEBO; PROBIOTIC AGENT; TACROLIMUS; TIOGUANINE;

ABDOMINAL ABSCESS; ACHILLES TENDON RUPTURE; ACNE; AGRANULOCYTOSIS; ARTHRALGIA; BONE DENSITY; BONE MARROW SUPPRESSION; BONE NECROSIS; CLINICAL TRIAL; COLON DISEASE; CONSENSUS; CROHN DISEASE; DIARRHEA; DIET THERAPY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG BINDING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DUODENUM DISEASE; DYSPEPSIA; EDEMA; EPIGASTRIC PAIN; ESOPHAGUS DISEASE; EUROPE; EVIDENCE BASED PRACTICE; FEVER; FLU LIKE SYNDROME; GLUCOSE INTOLERANCE; HEADACHE; HUMAN; ILEITIS; ILEUM POUCH; INFECTION; INFECTION SENSITIVITY; INTERSTITIAL NEPHRITIS; INTESTINE ANASTOMOSIS; JOINT STIFFNESS; LAPAROSCOPIC SURGERY; LEUKOPENIA; LIVER TOXICITY; LUNG ALVEOLITIS; MALAISE; META ANALYSIS; MOOD DISORDER; MOON FACE; MYALGIA; MYOPATHY; NAUSEA; NEPHROTIC SYNDROME; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PATIENT MONITORING; PATIENT SELECTION; PERCUTANEOUS DRAINAGE; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; RASH; RELAPSE; REMISSION; REVIEW; SEPSIS; SLEEP DISORDER; SMALL INTESTINE; STEVENS JOHNSON SYNDROME; STOMATITIS; SUBCAPSULAR CATARACT; SYSTEMATIC REVIEW; TENDINITIS; THROMBOCYTOPENIA; TUBERCULOSIS; VOMITING; ADRENAL INSUFFICIENCY; ANAPHYLAXIS; ARTICLE; CECUM DISEASE; CLINICAL EFFECTIVENESS; COLITIS; COLON CROHN DISEASE; DELAYED HYPERSENSITIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; EVIDENCE BASED MEDICINE; GASTRODUODENAL DISEASE; ILEOCOLITIS; INFLAMMATORY BOWEL DISEASE; INFUSION RELATED REACTION; LAPAROTOMY; LYMPHOMA; METALLIC TASTE; PRACTICE GUIDELINE; REFRACTORY PERIOD; SMALL INTESTINE DISEASE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACIDS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; CROHN DISEASE; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PATIENT SELECTION; PURINES; RECURRENCE; REMISSION INDUCTION;

EID: 33144459948     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.081950b     Document Type: Review

References (221)

1. Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126:1257-69.
2. Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-88.
3. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. New Engl J Med 1994;331:836-41.
4. Otley A, Steinhart AH, Otley A. Budesonide for induction of remission in Crohn's disease. Cochrane Library, Issue 4 Chichester: Wiley, 2005.
5. Thomsen OO, Cortot A, Jewell DP, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998;339:370-4.
6. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.
7. Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996;8:905-9.
8. Campieri M, Fergusonj A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997;41:209-14.
9. Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998;115:835-40.
10. Modigliani R, Mary JY, Simon JF, et al. Clinical biological and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-18.
11. Pearson DC, May GR, Pick GR, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Library, Issue 2 Oxford: Update Software 2000.
12. Fraser AG. Methotrexate: first or second-line immunomodulator? Eur J Gastroenterol Hepatol 2003;15:225-31.
13. Steinhart AH, Feagan B, Wong G, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33-40.
14. Summers RW, Switz DM, Sessions JT, et al. National co-operative Crohn's disease study group: results of drug treatment. Gastroenterology 1979;77:847-69.
15. Malchow H, Ewe K, Brandes JW, et al. European co-operative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
16. Sutherland LR, Singleton J, Sessions J, et al. Double-blind, placebo-controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-5.
17. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn's disease. Cochrane Library, Issue 3 Oxford: Update Software, 2001.
18. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985;88:1818-25.
19. Jess T, Winther KV, Munkholm P, et al. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 2002;122:1808-14.
20. Tremaine WJ. Gastroduodenal Crohn's disease: medical management. Inflamm Bowel Dis 2003;9:127-8.
21. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Library, Issue 1 Oxford: Update Software, 2003.
22. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002;359:1541-9.
23. Lémann M, Mary J-Y, Duclos B, et al. Infliximab as a bridge therapy in corticosteroid-dependent Crohn's disease patients treated with azathioprine. A randomized, double-blind, placebo-controlled trial. Gastroenterology (in press).
24. Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 2003;17:131-7.
25. Hommes DW, Baert F, Van Assche G, et al. Management of recent onset Crohn's disease: a controlled randomized trial comparing step-up and top-down therapy. Gastroenterology (in press).
26. Tremaine WJ, Schroeder KW, Harrison JM, et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994;19:278-82.
27. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993;104:1293-301.
28. Feagan BG. Editorial: 5-ASA therapy for active Crohn's disease: old friends, old data and a new conclusion. Clin Gastroenterol Hepatol 2004;2:376-8.
29. Ronsford RAJ, Longman MJS. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536-9.
30. Loftus EV, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19:179-89.
31. van Staa TP, Travis SPL, Leufkens HJM, et al. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiological study. Gastroenterology 2004;126:1733-9.
32. Ursing B, Alm T, Barony F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. Gastroenterology 1982;83:550-62.
33. Colombel JF, Lemann M, Cassagnou M, et al. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Am J Gastroenterol 1999;94:674-8.
34. Prantera C, Zonnoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-32.
35. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of anti-mycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000;95:725-9.
36. Brandt U, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study Gastroenterology 1982;83:383-7.
37. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
38. van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case control study. BMJ 2002;324:1306-7.
39. Schoon EJ, Bolloni S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 2005;3:110-12.
40. Aberra FN, Lewis JD, Mass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003;125:320-6.
41. British Society of Gastroenterology. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. Gut 2000;46(suppl 1):i1-8.
42. Compston J. Osteoporosis in inflammatory bowel disease. Gut 2003;52:63-4.
43. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
44. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.
45. Rutgeerts P, Van Assche G, Vermeire S. Optimising anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610.
46. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
47. Rampton DS. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy. Gut 2005;54:1360-2.
48. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
49. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
50. Lichtenstein GR, Cohen RD, Feagan BG, et al. Safety of infliximab in Crohn's disease: data from the 5000-patient TREAT registry. Gastroenterology 2004;126(suppl 2):A54.
51. Lichtenstein GR, Cohen RD, Feagan BG, et al. Safety of infliximab and other Crohn's disease therapies - Updated TREAT registry data with over 10 000 patient-years of follow-up. Gastroenterology 2005;128(suppl 2):A580.
52. Travis SPL. Advances in therapeutic approaches to ulcerative colitis and Crohn's disease. In: Hanauer SB, Richter JE, eds. Current Gastroenterology Reports 2005;7:475-84.
53. MacIntosh DG, Lukas M, Sandborn W, et al. A randomised, double-blind, placebo-controlled trial of the clinical assessment of adalimumab safety and efficacy studied as an induction therapy in Crohn's disease. Gut 2004;53(suppl VI):A47.
54. Schreiber S, Khaliq-Kareemi M, Lawrance I, et al. Certolizumab-pegol, a humanized anti-TNF pegylated Fab' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (PRECISE). Gut 2005;54(supplVII):A82.
55. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004;99:1984-9.
56. Sandborn WJ, Feagan B, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004;53:1485-93.
57. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
58. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25.
59. Van Assche G, Pearce T. Fontolizumab (Huzaftm), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease. Gut 2004;53(suppl VI):A48.
60. Mannon PJ, Fuss I, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-79.
61. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomised trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-96.
62. Braat H, Rottiers P, Huyghebaert N, et al. Inferleukin-10 producing Lactococcus lactis for the treatment of Crohn's disease. Gastroenterology 2005;128(suppl 2):A104.
63. Barkholt L, Lofberg R. Resetting the immune system in refractory Crohn's disease: autologous haemopoetic stem cell transplantation the way forward? Gastroenterology 2005;128:786-9.
64. + T lymphocytes. J Clin Invest 2003;111:1133-45.
65. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Library, Issue 2 Oxford: Update Software, 2000.
66. Sandborn W, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathiorpine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999;117:527-35.
67. Bebb JR, Scott BB. Systematic review: how effective are the usual treatments for Crohn's disease? Aliment Pharmacol Ther 2004;20:151-9.
68. McGovern DPB, Travis SPL. Thiopurine therapy: when to start and when to stop. Eur J Gastroenterol Hepatol 2003;15:219-24.
69. Lémann M, Mary JY, Colombel J-F, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812-18.
70. Sandborn WJ. Rational dosing or azathioprine and 6-mercaptopurine. Gut 2001;48:591-2.
71. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
72. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-9.
73. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for child-bearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003;124:9-17.
74. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5.
75. Kandiel A, Fraser AG, Korrelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5.
76. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24.
77. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate in the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
78. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
79. Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:57-63.
80. Hamilton RA, Kremer JM. Why intramuscular dosing may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86-90.
81. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 2004;43:267-71.
82. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000;95:3150-6.
83. Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989;321:845-50.
84. Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1994;330:1846-51.
85. Jewell DP, Lennard-Jones RE. Oral cyclosporine for chronic active Crohn's disease: a multi-centre controlled trial. Eur J Gastroenterol Hepatol 1994;6:499-506.
86. Stange EF, Modigliani R, Pena AS, et al. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. Gastroenterology 1995;109:774-82.
87. Hermida-Rodriguez C, Cantero Perona J, Garcia-Valriberas R, et al. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease. Hepatogastroenterologv 1999;46:2265-8.
88. Santos JV, Baudet JA, Casellas FJ, et al Intravenous cyclosporine for steroid-refractory attacks of Crohn's disease. Short- and long-term results. J Clin Gastroenterol 1995;20:207-10.
89. Egan LJ, Sandborn WJ, Tremaine Wj. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998;93:442-8.
90. Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001;15:371-7.
91. Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998;93:1860-6.
92. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997;92:876-9.
93. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease . Gastroenterology 2003;125:380-8.
94. Gassull MA, Cabre E. Nutrition in inflammatory bowel disease. Curr Opin Nutr Metab Care 2001;4:561-9.
95. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
96. Summers RW, Switz DM, Sessions JT Jr, et al. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979;77:847-69.
97. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-70.
98. Etienney I, Bouhnik Y, Gendre JP, et al. Crohn's disease over 20 years after diagnosis in a referral population. Gastroenterol Clin Biol 2004;28:1233-9.
99. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60.
100. Modigliani R, Mary JY, Simon JF, et al. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives (GETAID). Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Gastroenterology 1990;98:811-18.
101. Sahmoud T, Hoctin-Boes G, Modigliani R, et al. Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. Gut 1995;37:811-18.
102. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996;110:424-31.
103. Brignola C, Campieri M, Bazzocchi G, et al. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986;91:1490-4.
104. Brignola C, Iannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 1992;37:29-32.
105. Consigny Y, Modigliani R, Colombel JF, et al. Biological markers of short term relapse in Crohn's disease. Gastroenterology 2001;120:A141.
106. International Mesalamine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 1990;4:55-64.
107. Bondesen S, Hegnhoj J, Larsen F, et al. Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per as slow-release formulation. Dig Dis Sci 1991;36:1735-40.
108. Bresci G, Petrucci A, Banti S. 5-aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study. Int J Clin Pharmacol Res 1991;11:200-2.
109. Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. Gastroenterology 1992;103:363-8.
110. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993;104:435-9.
111. Arber N, Odes HS, Fireman Z, et al. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol 1995;20:203-6.
112. Thomson AB, Wright JP, Vatn M, et al. Mesalazine (Mesasal/Claversal) 1.5 g bd vs placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther 1995;9:673-83.
113. Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996;110:688-93.
114. de Franchis R, Omodei P, Ranzi T, et al. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. Aliment Pharmacol Ther 1997;11:845-52.
115. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997;112:1069-77.
116. Mahmud N, Kamm MA, Dupas JL, et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut 2001;49:552-6.
117. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89:2116-24.
118. Messori A, Brignola C, Trallori, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89:692-8.
119. Comma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73.
120. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Library, Issue I Chichester, Wiley, 2005.
121. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintaining remission of Crohn's disease. Cochrane Library, Issue 4 Oxford: Update Software, 2003.
122. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996;39:82-6.
123. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996;110:45-51.
124. Ferguson A, Campieri M, Doe W, et al. Oral budesonide as maintenance therapy in Crohn's disease-results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998;12:175-83.
125. Gross V, Andus T, Ecker KW, et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. Gut 1998;42:493-6.
126. Caprilli R, Angelucci E, Cocco A, et al. Appropriateness of immunosuppressive drugs in inflammatory bowel disease assessed by RAND method: Italian Group for IBD position statement. Dig Liver Dis 2005;37:407-17.
127. Papi C, Luchetti R, Montanti S, et al. Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther 2000;14:1419-28.
128. Simms L, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease. Cochrane Library, Issue 4 Oxford: Update Software, 2001.
129. Green JR, Lobo AJ, Giaffer M, et al. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules. Aliment Pharmacol Ther 2001;15:1331-41.
130. Sandborn WJ, Lofberg R, Feagan B, et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005;100:1780-7.
131. Elliott PR, Burnham WR, Berghouse LM, et al. Sulphadoxine-pyrimethamine therapy in Crohn's disease. Digestion 1982;23:132-4.
132. Shaffer JL, Hughes S, Linaker BD, et al. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 1984;25:203-5.
133. Basilisco G, Campanini M, Cesana B, et al. Controlled trial of rifabutin in Crohn's disease. Curr Therap Res 1989;46:245-50.
134. Afdhal NH, Long A, Lennon J, et al. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci 1991;36:449-53.
135. Prantera C, Kohn A, Mangiarotti R, et al. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994;89:513-18.
136. Swift GL, Srivastava ED, Stone R, et al. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 1994;35:363-8.
137. Goodgame RW, Kimball K, Akram S, et al. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther 2001;15:1861-6.
138. Borgaonkar M, MacIntosh D, Fardy J, et al. Anti-tuberculous therapy for maintaining remission of Crohn's disease. Cochrane Library, Issue 4 Oxford: Update Software, 2001.
139. Willoughby JM, Beckett J, Kumar PJ, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;ii:944-7.
140. Rosenberg JL, Levin B, Wall AJ, et al. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975;20:721-6.
141. O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease, Lancet 1978;ii:955-7.
142. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
143. Treton X, Bouhnik Y, Mary Jy, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission under treatment is associated with a high risk of relapse. Gastroenterology 2004;126(suppl 2):A113.
144. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-42.
145. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Library, Issue 4 Oxford: Update Software, 2001.
146. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001;7:181-9.
147. Bonaz B, Boitard J, Marteau P, et al. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003;15:401-8.
148. Herrlinger KR, Deibert P, Schwab M, et al. Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment Pharmacol Ther 2003;15:1459-64.
149. Geller SA, Dubinsky MC, Poordad FF, et al. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol 2004;28:1204-11.
150. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003;125:298-303.
151. Seiderer J, Reinisch W, Zech C, et al. Nodular regenerative hyperplasia in IBD patients on 6-thioguanine - a multi-centre safety assessment by MRI and liver biopsy. Gastroenterology 2004;126:813.
152. Rulyak SJ, Sounders MD, Lee SD. Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease. J Clin Gastroenterol 2003;36:234-7.
153. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724-9.
154. Lémann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000;95:1730-4.
155. Fraser AG, Morton D, McGovern D, et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:693-7.
156. Stange EF, Modigliani R, Pena AS, et al. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. Gastroenterology 1995;109:774-82.
157. Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1994;330:1846-51.
158. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
159. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
160. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001;120:1330-8.
161. Feagan B, Sandboen WJ, Baker JP, et al. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 2005;21:373-84.
162. Lorenz-Meyer H, Bauer P, Nicolay C, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol 1996;31:778-85.
163. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334:1557-60.
164. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4.
165. Lerebours E, Bussel A, Modigliani R, et al. Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1994;107:357-61.
166. Dewit O, Vanheuverzwyn R, Desager JP, et al. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:79-85.
167. Breuer-Katschinski BD, Hollander N, Goebell H. Effect of cigarette smoking on the course of Crohn's disease. Eur J Gastroenterol Hepatol 1996;8:225-8.
168. Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol 2002;97:915-21.
169. Stockbrugger RW, Schoon E, Bollani S, et al. Budesonide versus prednisolone in the management of Crohn's disease: a randomized multinational 2-year study. Gastroenterology 2003;124:A181.
170. Heuman R, Boeryd B, Bolin T, et al. The influence of disease at the margin of resection on the outcome of Crohn's disease. Br J Surg 1983;70:519-21.
171. Graadal O, Nygaard K. [Crohn disease. Long-term effects of surgical treatment]. Tidsskr Nor Laegeforen 1994;114:1603-5.
172. Nordgren SR, Fasth SB, Oresland TO, et al. Long-term follow-up in Crohn's disease. Mortality, morbidity, and functional status. Scand J Gastroenterol 1994;29:1122-8.
173. Weston LA, Roberts PL, Schoetz DJ Jr, et al. Ileocolic resection for acute presentation of Crohn's disease of the ileum. Dis Colon Rectum 1996;39:841-6.
174. Kim NK, Senagore AJ, Luchtefeld MA, et al. Long-term outcome after ileocecal resection for Crohn's disease. Am Surg 1997;63:627-33.
175. Tillinger W, Mittermaier C, Lochs H, et al. Health-related quality of life in patients with Crohn's disease: influence of surgical operation-a prospective trial. Dig Dis Sci 1999;44:932-8.
176. Gervais DA, Hahn PF, O'Neill MJ, et al. Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14 years. Radiology 2002;222:645-51.
177. Garcia JC, Persky SE, Bonis PA, et al. Abscesses in Crohn's disease: outcome of medical versus surgical treatment. J Clin Gastroenterol 2001;32:409-12.
178. Yamaguchi A, Matsui T, Sakurai T, et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn's disease. J Gastroenterol 2004;39:441-8.
179. Michelassi F, Upadhyay GA. Side-to-side isoperistaltic strictureplasty in the treatment of extensive Crohn's disease. J Surg Res 2004;117:71-8.
180. Sampietro GM, Sartani A, Danelli P, et al. [Strictureplasty in the surgical treatment of complicated Crohn's disease]. Ann Ital Chir 2003;74:659-63.
181. Tonelli F, Fedi M, Paroli GM, et al. Indications and results of side-to-side isoperistaltic strictureplasty in Crohn's disease. Dis Colon Rectum 2004;47:494-501.
182. Shatari T, Clark MA, Yamamoto T, et al. Long strictureplasty is as safe and effective as short strictureplasty in small-bowel Crohn's disease. Colorectal Dis 2004;6:438-41.
183. Poggioli G, Laureti S, Pierangeli F, et al. A new model of strictureplasty for multiple and long stenoses in Crohn's ileitis: side-to-side diseased to disease-free anastomosis. Dis Colon Rectum 2003;46:127-30.
184. Tichansky D, Cagir B, Yoo E, et al. Strictureplasty for Crohn's disease: meta-analysis. Dis Colon Rectum 2000;43:911-19.
185. Hashemi M, Novell JR, Lewis AA. Side-to-side stapled anastomosis may delay recurrence in Crohn's disease. Dis Colon Rectum 1998;41:1293-6.
186. Munoz-Juarez M, Yamamoto T, Wolff BG, et al. Wide-lumen stapled anastomosis vs. conventional end-to-end anastomosis in the treatment of Crohn's disease. Dis Colon Rectum 2001;44:20-5.
187. Scarpa M, Angriman I, Barollo M, et al. Role of stapled and hand-sewn anastomoses in recurrence of Crohn's disease. Hepatogastroenterology 2004;51:1053-7.
188. Yamamoto T, Bain IM, Mylonakis E, et al. Stapled functional end-to-end anastomosis versus sutured end-to-end anastomosis after ileocolonic resection in Crohn disease. Scand J Gastroenterol 1999;34:708-13.
189. Tersigni R, Alessandroni L, Barreca M, et al. Does stapled functional end-to-end anastomosis affect recurrence of Crohn's disease after ileocolonic resection? Hepatogastroenterology 2003;50:1422-5.
190. Scott NA, Sue-Ling HM, Hughes LE. Anastomotic configuration does not affect recurrence of Crohn's disease after ileocolonic resection. Int J Colorectal Dis 1995;10:67-9.
191. Ikeuchi H, Kusunoki M, Yamamura T. Long-term results of stapled and hand-sewn anastomoses in patients with Crohn's disease. Dig Surg 2000;17:493-6.
192. Benoist S, Panis Y, Beaufour A, et al. Laparoscopic ileocecal resection in Crohn's disease: a case-matched comparison with open resection. Surg Endosc 2003;17:814-18.
193. Marcello PW, Milsom JW, Wong SK, et al. Laparoscopic restorative proctocolectomy: case-matched comparative study with open restorative proctocolectomy. Dis Colon Rectum 2000;43:604-8.
194. Tabet J, Hong D, Kim CW, et al. Laparoscopic versus open bowel resection for Crohn's disease. Can J Gastroenterol 2001;15:237-42.
195. Young-Fodok TM, HallLong K, McConnell EJ, et al. Advantages of laparoscopic resection for ileocolic Crohn's disease. Improved outcomes and reduced costs. Surg Endosc 2001;15:450-4.
196. Milsom JW, Hammerhofer KA, Bohm B, et al. Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn's disease. Dis Colon Rectum 2001;44:1-8.
197. Bernell O, Lapidus A, Hellers G. Recurrence after colectomy in Crohn's colitis. Dis Colon Rectum 2001;44:647-54.
198. Allan A, Andrews H, Hilton CJ, et al. Segmental colonic resection is an appropriate operation for short skip lesions due to Crohn's disease in the colon. World J Surg 1989;13:611-4.
199. Yamamoto T, Keighley MR. Proctocolectomy is associated with a higher complication rate out carries a lower recurrence rate than total colectomy and ileorectal anastomosis in Crohn colitis. Scand J Gastroenterol 1999;34:1212-15.
200. Tonelli F, Paroli GM. [Colorectal Crohn's disease: indications to surgical treatment]. Ann Ital Chir 2003;74:665-72.
201. Longo WE, Ballantyne GH, Cahow CE. Treatment of Crohn's colitis. Segmental or total colectomy? Arch Surg 1988;123:588-90.
202. Andersson P, Olaison G, Hallbook O, et al. Segmental resection or subtotal colectomy in Crohn's colitis? Dis Colon Rectum 2002;45:47-53.
203. Morini S, Hassan C, Lorenzetti R, et al. Long-term outcome of endoscopic pneumatic dilatation in Crohn's disease. Dig Liver Dis 2003;12:851-2.
204. Breysem Y, Janssens JF, Coremans G, et al. Endoscopic balloon dilation of colonic and ileo-colonic Crohn's strictures: long-term results. Gastrointest Endosc 1992;38:142-7.
205. Thomas-Gibson S, Brooker JC, Hayward CM, et al. Colonoscopic balloon dilation of Crohn's strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol 2003;15:485-8.
206. Broering DC, Eisenberger CF, Koch A, et al. Strictureplasty for large bowel stenosis in Crohn's disease: quality of life after surgical therapy. Int J Colorectal Dis 2001;16:81-7.
207. de Oca J, Sanchez-Santos R, Rague JM, et al. Long-term results of ileal pouch-anal anastomosis in Crohn's disease. Inflamm Bowel Dis 2003;9:171-5.
208. Sogar PM, Dozois RR, Wolff BG. Long-term results of ileal pouch-anal anastomosis in patients with Crohn's disease. Dis Colon Rectum 1996;39:893-8.
209. Handelsman JC, Gottlieb LM, Hamilton SR. Crohn's disease as a contraindication to Kock pouch (continent ileostomy). Dis Colon Rectum 1993;36:840-3.
210. Hyman NH, Fazio VW, Tuckson WB, et al. Consequences of ileal pouch-anal anastomosis for Crohn's colitis. Dis Colon Rectum 1991;34:653-7.
211. Mylonakis E, Allan RN, Keighley MR. How does pouch construction for a final diagnosis of Crohn's disease compare with ileoproctostomy for established Crohn's proctocolitis? Dis Colon Rectum 2001;44:1137-42.
212. Panis Y, Poupard B, Nemeth J, et al. Ileal pouch/anal anastomosis for Crohn's disease. Lancet 1996;347:854-7.
213. Regimbeau JM, Panis Y, Pocard M, et al. Long-term results of ileal pouch-anal anastomosis for colorectal Crohn's disease. Dis Colon Rectum 2001;44:769-78.
214. Marchai L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749-54.
215. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878-83.
216. Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn's disease. Dis Colon Rectum 2000;43:1141-5.
217. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003;125:320-7.
218. Mahadevan U, Loftus EV Jr, Tremaine WJ, et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002;8:311-16.
219. Heuschen UA, Hinz U, Allemeyer EH, et al. Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis. Ann Surg 2002;235:207-16.
220. Toy GS, Binion DG, Eastwood D, et al. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or Strictureplasty. Surgery 2003;134:565-72.
221. Myrelid P, Andersson P, Sjodahl R, et al. Immunosuppression for Crohn's disease is associated with increased frequency of anastomotic complications. Colorectal Disease 2004;6:26.